Mental Health DailyResearch. Evidence. Perspective.Published research on weight neutral.
Rexulti (Brexpiprazole), is an atypical antipsychotic that was jointly developed by pharmaceutical companies Otsuka and Lundbeck. In 2015, the FDA approved Rexulti for the treatment of schiz…
Read articleGeodon (Ziprasidone) is an atypical antipsychotic that was approved by the FDA in 2001 for the treatment of schizophrenia. It has since been approved to manage both manic and mixed states of…
Read articleLatuda (Lurasidone) is a relatively new atypical antipsychotic that was approved in 2013 for the treatment of schizophrenia and depressive episodes in Type 1 Bipolar disorder. Many have made…
Read articleViibryd (Vilazodone) is a drug that was developed by Merck for the treatment of clinical depression. It was approved in the United States as an antidepressant medication in 2011. It function…
Read article